methyl 2,2-dimethyltetradecanoate | 1313869-39-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 2,2-dimethyltetradecanoate
• CAS: 1313869-39-4
• 化学式: C₁₇H₃₄O₂
• 分子量: 270.456
• InChiKey: YVNJZSQXEFBIAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  19
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 2,2-dimethyltetradecanoate 在 乙醇 、 sodium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 生成 2,2-二甲基十四烷酸
  参考文献：
  名称：

  Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders

  摘要：

  本发明提供了二苯并二氮杂苯类药物化合物的前药化合物。

  公开号：

  US20110166128A1
• 作为产物：
  描述：

  1-碘十二烷 、 异丁酸甲酯 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 反应 1.5h， 生成 methyl 2,2-dimethyltetradecanoate
  参考文献：
  名称：

  Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders

  摘要：

  本发明提供了二苯并二氮杂苯类药物化合物的前药化合物。

  公开号：

  US20110166128A1

文献信息

• Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US20200353090A1

  公开（公告）日：2020-11-12

  The invention relates to new prodrugs of active molecules. These prodrugs allow, in particular, the subcutaneous or intramuscular administration of active molecules of which the subcutaneous or intramuscular administration is problematic or impossible, in particular because of the toxicity at the injection site. The prodrugs according to the invention comprise an active ingredient, covalently linked with a polymer chain, preferably a hydrophilic and/or thermosensitive polymer chain. The invention relates, in particular, to polymeric prodrugs comprising a polymer chain formed at least in part by acrylamide monomer or one of its derivatives, the polymer comprising a proximal part and a terminal part; a first pharmaceutically active molecule covalently coupled to the proximal part of the polymer; possibly a second pharmaceutically active molecule covalently coupled to the terminal part of the polymer.

  该发明涉及新型活性分子的前药。这些前药允许特别是将活性分子皮下或肌肉内注射，而这些活性分子的皮下或肌肉内注射由于在注射部位的毒性而具有问题或不可能，特别是由于在注射部位的毒性。根据本发明的前药包括一种活性成分，与一根聚合物链共价连接，优选为一种亲水性和/或热敏感性聚合物链。该发明特别涉及包括由丙烯酰胺单体或其衍生物之一至少部分形成的聚合物链的聚合物前药，该聚合物包括一个近端部分和一个末端部分；第一种药用活性分子共价结合到聚合物的近端部分；可能第二种药用活性分子共价结合到聚合物的末端部分。
• Prodrugs for the Treatment of Schizophrenia and Bipolar Disease
  申请人：Blumberg Laura Cook

  公开号：US20110166156A1

  公开（公告）日：2011-07-07

  Compounds of Formula I and Formula II and their use for the treatment of neurological and psychiatric disorders including schizophrenia and manic or mixed episodes associated with bipolar I disorder with or without psychotic features is disclosed.

  本文披露了公式I和公式II的化合物及其用于治疗神经系统和精神障碍，包括与双相I型障碍伴有或不伴有精神症状的精神分裂症和躁狂或混合发作的治疗。
• Asenapine Prodrugs
  申请人：Blumberg Laura Cook

  公开号：US20110166194A1

  公开（公告）日：2011-07-07

  Compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia and manic or mixed episodes associated with bipolar I disorder with or without psychotic features is disclosed: wherein R 1 -R 8 , G, N and A − are as defined in the written description.

  公开了式I的化合物及其用于治疗神经和精神障碍，包括精神分裂症和与带或不带精神症状的双相I障碍相关的躁狂或混合发作：其中R1-R8，G，N和A-如书面描述中所定义。
• Quaternary Ammonium Salt Prodrugs
  申请人：Almarsson Orn

  公开号：US20110178068A1

  公开（公告）日：2011-07-21

  The invention provides a method of sustained delivery of a tertiary amine-containing parent drug comprising administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile quaternary ammonium salts of tertiary amine-containing parent drugs (or tertiary imine-containing parent drugs) that are derivatized through aldehyde-linked prodrug moieties that reduce the solubility of the prodrug compound at a reference pH as compared to the parent drug. The physical, chemical and solubility properties of these derivatives can be further modulated by the choice of counterion X − . In one embodiment, the present invention provides a prodrug compound of Formula I: where R 1 -R 5 are defined in the written description of the invention. The prodrug compounds of the invention can be used to treat any condition for which the tertiary amine-containing parent drug or tertiary imine-containing parent drug is useful as a treatment.

  本发明提供了一种持续释放三级胺含有的母药的方法，包括向患者施用本发明的前药化合物的有效量，其中在向患者施用时，母药从前药中的释放是持续释放的。适用于本发明方法的前药化合物是由醛基连接的前药基团衍生的，这些前药基团可以减少前药化合物在参考pH下的溶解度与母药相比。这些衍生物的物理、化学和溶解度特性可以通过选择阴离子X-来进一步调节。在一种实施方式中，本发明提供了式I的前药化合物：其中R1-R5在发明的书面描述中被定义。本发明的前药化合物可用于治疗任何需要使用三级胺含有的母药或三级亚胺含有的母药进行治疗的情况。
• Livestock products with an increased ppar/rxr heterodimer activator level
  申请人：De Keyser Luc

  公开号：US20060167096A1

  公开（公告）日：2006-07-27

  In the non-therapeutic method livestock animals, used in agri- or aquaculture for producing livestock products, are made to ingest at least one product comprising a PPAR/RXR heterodimer activator and/or a precursor thereof over such a period of time and in such an amount that the PPAR/RXR heterodimer activator is accumulated in the livestock animal. In this way, livestock products such as meat, milk and eggs having an increased PPAR/RXR heterodimer activator level can be obtained. The PPAR/RXR heterodimer activator is phytanic acid, a metabolite of phytanic acid, a derivative of phytanic acid or of said metabolite, or a combination thereof. In order to accumulate the PPAR/RXR heterodimer activator in the livestock animal, a predetermined minimum amount of said product, in particular of phytol, is given to the livestock animals over at least one period of at least three days.

  在非治疗方法中，农业或水产养殖业中用于生产畜产品的牲畜，要在一定时间内摄入至少一种包含 PPAR/RXR 异源二聚体激活剂和/或其前体的产品，摄入量要使 PPAR/RXR 异源二聚体激活剂在牲畜体内积累。这样，就能获得 PPAR/RXR 杂二聚体活化剂水平提高的肉类、奶类和蛋类等畜产品。PPAR/RXR 杂二聚体活化剂是植烷酸、植烷酸的代谢物、植烷酸或上述代谢物的衍生物或它们的组合。为了在牲畜体内积累 PPAR/RXR 二聚体异质激活剂，至少在三天内向牲畜施用预定最低量的上述产品，特别是植烷醇。